Adverse event profiles of adjuvant treatment with opicapone in Parkinson's disease: A systematic review and meta-analysis.
Ontology highlight
ABSTRACT: Background: Opicapone, a novel third-generation catechol-O-methyltransferase inhibitor, has demonstrated efficacy in Parkinson's Disease (PD) patients with end-of-dose motor fluctuations. Objective: This study aimed to compare the short-term (<6 months) and long-term (≥6 months) tolerability of opicapone adjuvant treatment in PD patients. Method: Electronic databases including PubMed, Embase, Web of Science and Cochrane library were searched for randomized controlled trials (RCTs) and observational studies. The end points included any treatment-related adverse events (TEAEs), serious TEAEs (SAEs) and treatment discontinuation. A random-effects model was used to generate overall incidences of TEAE. Results: Three RCTs, three RCT extension studies and three open-l
SUBMITTER: Xie L
PROVIDER: S-EPMC9729693 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
ACCESS DATA